Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet licensed by the MHRA or EMA for use in the UK
Additional research has also found benefits for kidney disease and obstructive sleep apnea in select patient populations
In the UK, NICE (the National Institute for Health and Care Excellence) would subsequently evaluate the clinical and cost-effectiveness of retatrutide before recommending whether it should be made available on the NHS
Our Ozempic lawyers are consistently investigating the side effects of GLP-1 drugs
Heres how to respond
We explore all angles ancient wisdom, modern science, and everything in between with no allegiance to Big Pharma or Big Natural
US$ 24.36
US$ 22.91
US$ 29.05
